Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

LRG2.1_Neo Citations (7)

Originally described in: Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo.
Tarumoto Y, Lin S, Wang J, Milazzo JP, Xu Y, Lu B, Yang Z, Wei Y, Polyanskaya S, Wunderlich M, Gray NS, Stegmaier K, Vakoc CR Blood. 2019 Nov 1. pii: 422697. doi: 10.1182/blood.2019001576.
PubMed Journal

Articles Citing LRG2.1_Neo

Articles
ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Somerville TDD, Xu Y, Wu XS, Maia-Silva D, Hur SK, de Almeida LMN, Preall JB, Koo PK, Vakoc CR. Proc Natl Acad Sci U S A. 2020 May 26;117(21):11471-11482. doi: 10.1073/pnas.1921484117. Epub 2020 May 8. PubMed
High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. Gier RA, Budinich KA, Evitt NH, Cao Z, Freilich ES, Chen Q, Qi J, Lan Y, Kohli RM, Shi J. Nat Commun. 2020 Jul 13;11(1):3455. doi: 10.1038/s41467-020-17209-1. PubMed

Associated Plasmids

Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. Xu C, Tsai YH, Galbo PM, Gong W, Storey AJ, Xu Y, Byrum SD, Xu L, Whang YE, Parker JS, Mackintosh SG, Edmondson RD, Tackett AJ, Huang J, Zheng D, Earp HS, Wang GG, Cai L. Nucleic Acids Res. 2021 May 21;49(9):4971-4988. doi: 10.1093/nar/gkab252. PubMed
BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation. Conway E, Rossi F, Fernandez-Perez D, Ponzo E, Ferrari KJ, Zanotti M, Manganaro D, Rodighiero S, Tamburri S, Pasini D. Mol Cell. 2021 Sep 2;81(17):3526-3541.e8. doi: 10.1016/j.molcel.2021.06.020. Epub 2021 Jun 28. PubMed
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Wang J, Yu X, Gong W, Liu X, Park KS, Ma A, Tsai YH, Shen Y, Onikubo T, Pi WC, Allison DF, Liu J, Chen WY, Cai L, Roeder RG, Jin J, Wang GG. Nat Cell Biol. 2022 Mar;24(3):384-399. doi: 10.1038/s41556-022-00850-x. Epub 2022 Feb 24. PubMed
Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2. Hanley RP, Nie DY, Tabor JR, Li F, Sobh A, Xu C, Barker NK, Dilworth D, Hajian T, Gibson E, Szewczyk MM, Brown PJ, Barsyte-Lovejoy D, Herring LE, Wang GG, Licht JD, Vedadi M, Arrowsmith CH, James LI. J Am Chem Soc. 2023 Apr 12;145(14):8176-8188. doi: 10.1021/jacs.3c01421. Epub 2023 Mar 28. PubMed
p73 activates transcriptional signatures of basal lineage identity and ciliogenesis in pancreatic ductal adenocarcinoma. Hur SK, Somerville TDD, Wu XS, Maia-Silva D, Demerdash OE, Tuveson DA, Notta F, Vakoc CR. bioRxiv. 2023 Apr 21:2023.04.20.537667. doi: 10.1101/2023.04.20.537667. Preprint. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.